Success in Rare Disease: Patient Involvement Matters!
This past December, the FDA finalized its guidance on rare diseases with the…
Juggling Geographic Commercialization Priorities
Commercializing a pharmaceutical asset in one country is hard enough. Doing it…
Happy Anniversary to Us!
I grew up in the Midwest — the middle child in a large family. We were each…
Hybrid Work Strategies: 3 Tips to Transform Engagement
In this post-COVID era, our clients have experienced a culture shift — driven…
Rare Disease Patient Advocacy and Medical Affairs: Why They Come First
Among all the days of the calendar, February 29th is the rarest of them all. That's why, back in 2008, on the 25th anniversary of the Orphan Drug…
Planning Amidst the Mayhem
Maybe you noticed – 2020 was a crazy year. Like meeting the Pope or becoming a parent for the first time, the phrase "once in a lifetime" keeps…
Just Do It… the Best You Can with Compassion for Others AND Yourself
With six weeks left in the year, this newsletter should be all about getting in gear for the 2021 planning cycle. Or, maybe, it should be about Q1,…
Reverse Mentoring with Up-and-Coming Talent
In the accelerated, high-stakes world of biopharma, thinking big, thinking fast, and thinking smart, isn’t just an option — it’s a priority. Why…
How to Write the Biopharma S-1 Business Section
Over the past several years, The NemetzGroup has worked with numerous clients to develop key aspects of their S-1 filings — coordinating with…
There Is No Such Thing as a Free Launch!
We are fortunate to work with clients of all sizes, whose products are at various stages of their life cycle. But the angst around how to achieve a…
Making Virtual Workshops Work
Workshops, whether in the form of a half-day strategy session, a company-wide offsite or some other configuration, have one thing in common: They…